The Relation Between Hla-G And Cancer

Yıl 2012, Cilt: 14 Sayı: 2, 70 - 74, 01.07.2012

Ramazan Memişoğulları Taner Uçgun Hilmi Demirin M Engin Özcan

Öz

The importance of HLA antigens on immunity and tissue compatibility is known. The suppressorrole of a non classical HLA antigen HLA-G is being clearer with the results of last studies. Onnormal situations its being is restricted in a few type of tissue. It can be found on fetal tissueslike trophoblasts, tymic medulla, cornea, pancreatic islets and precursors of erithroid andendothelial cells. The expression of HLA-g is increased in the situations like malignities,transplantation, multiple sclerosis, inflammatory diseases and viral infections. In this review itis aimed to give short information on HLA system and to introduce the studies pronouncing therelation of HLA-G and malignities

Anahtar Kelimeler

HLA-G, cancer, tumor immunity

Hla-G Ve Kanser İlişkisi

Öz

HLA antijenlerinin doku uyumu ve immünite açısından önemi bilinmektedir. HLA sınıf 1antijenlerinden non-klasik gruba dâhil olan HLA-G’nin kanser immunitesindeki baskılayıcı rolüson zamanlarda yapılan çalışmalarda daha da açığa çıkarılmıştır. HLA-G normal durumlardaçok kısıtlı dokularda bulunmaktadır. Trofoblastlar gibi fetal dokularda, timik medulla, kornea,pankreatik adacıklarda ve eritroid ve endotelial hücre prekürsörlerinde bulunmaktadır. HLA-Gekspresyonu bu fizyolojik durumların dışında kanserler, transplantasyon, multiple scleroz,inflamatuar hastalıklar ve viral enfeksiyonlar gibi patolojik durumlarda da artmış seviyelerdedir.Bu derlemede HLA sistemi hakkında kısaca bilgi verilerek HLA-G ile kanser ilişkisinivurgulayan farklı kanser türleri üzerinde yapılmış çalışmaları ortaya koymak amaçlanmıştır

Anahtar Kelimeler

HLA-G, kanser, tumör immunitesi

Kaynakça

• Akçam F.Z. HLA sistemi. Türkiye klinikleri J Med Sci. 2005;25:829-34.
• Beksaç M. HLA ve doku tiplendirmesi Türk Hematoloji Derneği kan ve kemik iliği transplantasyonu kursu notları (sayfa http://www.thd.org.tr/doc/kurs_pdf/hlavedokutiplendirilmesi.p df (Erişim tarihi 26.10.2011). 42-49)
• Amiot L, Ferrone S, Grosse-Wilde H, Seliger B. Biology of HLA-G in cancer: a candidate molecule for therapeutic intervention? Cell Mol Life Sci. 2011;68:417-31.
• Edgardo DC, Benoit F, Nathalie RF, Moreau P, LeMaoult J. Beyond the increasing complexity of the immunomodulatory HLA-G molecule. Blood. 2008;111:4862-70.
• Schütt P, Schütt B, Switala M, et al. Prognostic relevance of soluable human leukocyte antigen–G and total human leukocyte antigen clas I molecules in lung cancer patients. Hum Immunol. 2010;71:489-95.
• Seliger B. Schlaf G: Structure, expression and function of HLA-G in renal cell carcinoma. Semin Cancer Biol. 2007;17:444-50.
• Evans C, Dalgleish AG, Kumar D. Review article: immune supression and colorectal cancer. Aliment Pharmacol Ther. 2006;24,1163-77.
• Wiendl H, Mitsdoerffer M, Weller M. Hide-and-seek in the brain: arole for HLA-G mediating immune privilege for glioma cells. Semin Cancer Biol. 2003;13:343-51.
• Robert LE, Xian PJ, Jeffrey TP, Brian GB, Jonathan FH. Human Leukocyte Antigen G Expression in Breast Cancer: Role in Immunosuppression cancer biotherapy and radiopharmaceutıcals. 2011;26(2):153-7.
• Pistoia V, Morandi F, Wang X, Ferrone S. Soluable HLA-G are they clinically relevant? Semin Cancer Biol. 2007;17:469- 79.
• Yie S , Hu Z. Human Leukocyte Antigen-G (HLA-G) as a marker for diagnosis, prognosis and tumor immune escape in human malignancies. Histol Histolpathol. 2011;26:409-20.
• Soluable HLA-G ELisa Data Sheet Biovendor Research And Diagnostic Products.
• Rebmann V, Regel J, Stolke D, Grosse-Wilde H. Secretion of sHLA-G molecules in malignancies. Semin Cancer Biol. 2003;13:371–7.
• Ugurel S, Rebmann V, Ferrone S, Tilgen W, Grosse-Wilde H, Reinhold U. Soluble human leukocyte antigen—G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy. Cancer. 2001;92(2):369-76.
• Lesport E, Baudhuin J, LeMaoult J, et al. Human melanoma cell secreting human leukocyte antigen-G5 inhibit natural killer cell cytotoxicity by impairing lytic granules polarization toward target cell. Hum Immunol. 2009;70(12):1000-5.
• Gros F, Sebti Y, Guibert S, et al. Soluble HLA-G Molecules Are Increased during Acute Leukemia, Especially in Subtypes Affecting Monocytic and Lymphoid Lineages. Neoplasia. 2006;8:223–30.
• Urosevic M, Willers J, Mueller B. HLA-G protein up- regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas. Blood. 2002;99:609-17.
• Erikci AA, Karagoz B, Ozyurt M, Ozturk A, Kilic S, Bilgi O. HLA-G expression in B chronic lymphocytic leukemia: a new prognostic marker? Hematology. 2009;14(2):101-5.
• Giannopoulos K, Dmoszyńska A, Bojarska-Junak A, Schmitt M, Roliński J. Expression of HLA-G in patients with B-cell chronic lymphocytic leukemia (B-CLL). Folia Histochem Cytobiol. 2008;46(4):457-60.
• Sebti Y, Le Friec G, Pangault C, et al. Soluble HLA-G molecules are increased in lymphoproliferative disorders. Hum Immunol. 2003;64(11):1093-101.
• Chen H , Lin A, Shen C. Upregulation of human leukocyte antigen–G expression and its clinical significance in ductal breast cancer. Hum Immunol. 2010;71:892–8.
• Sayed D, Badr G, Maximous D. HLA-G and its relation to proliferation index in and monitoring breast cancer patients. Tissue Antigens. 2010;75: 40-7.
• Zhu C, Wang C, Zhang X. Serum sHLA-G levels: a useful indicator in distinguishing colorectal cancer from benign colorectal diseases. Int J Cancer. 2011;128:617–22.
• Lin A, Zhu CC, Chen HX, et al. Clinical relevance and functional implications for human leucocyte antigen-g expression in non-small-cell lung cancer. J Cell Mol Med. 2010;14(9):2318-29.